Study suggests new hope for pulmonary hypertension
Halo Biosciences has announced publication of results in Thorax from the Phase IIa SATURN study for patients with pulmonary hypertension and interstitial lung disease (PH-ILD). The study, conducted at Stanford University, evaluated 4-methylumbelliferone (4-MU) in patients with pulmonary hypertension, a highly progressive disease with significant unmet needs. The Phase IIa… Read More